Atlas Trials

Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors

Clinical trial NCT06408688 · RECRUITING

Trial details

NCT number
NCT06408688
Sponsor
University Hospital, Basel, Switzerland
Status
RECRUITING
Phase
Phase 4
Study type
INTERVENTIONAL
Advanced Solid Tumor
Start date
2024-06-24
Primary completion
2026-11-01
Enrollment
100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.